A new cancer vaccine trains the immune system to recognize and attack tumor cells. The vaccine, autogene cevumeran, has demonstrated sustained immune activity in a small phase 1 clinical trial for pancreatic cancer. According to new findings published in Nature, the vaccine successfully activated tumor-specific immune cells that remained in patients’ bodies for up to four years. Those who had a strong immune response showed a lower risk of cancer recurrence compared to non-responders. This promising approach, developed by Memorial Sloan Kettering Cancer Center (MSK) in collaboration with BioNTech and Genentech, personalizes the vaccine to each patient's tumor, training the immune system to recognize and attack cancer cells. With pancreatic cancer being one of the deadliest malignancies, new therapies are urgently needed. The phase 2 clinical trial, now underway, is evaluating the vaccine's effectiveness in a larger group of patients.